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Abstract
Purpose Health-related quality of life (HRQOL) can be
significantly impaired by the presence of chronic condi-
tions such as cardiovascular disease (CVD) and major
depressive disorder (MDD). The aim of this paper was to
(1) identify differences in HRQOL between individuals
with CVD, MDD, or both, compared to a healthy reference
group, (2) establish whether the influence of co-morbid
MDD and CVD on HRQOL is additive or synergistic and
(3) determine the way in which depression severity inter-
acts with CVD to influence overall HRQOL.
Methods Population-based data from the 2007 Australian
National Survey of Mental Health and Well-being
(NSMHWB) (n = 8841) were used to compare HRQOL of
individuals with MDD and CVD, MDD but not CVD, CVD
but not MDD, with a healthy reference group. HRQOL was
measured using the Assessment of Quality of Life (AQOL).
MDD was identified using the Composite International
Diagnostic Interview (CIDI 3.0).
Results Of all four groups, individuals with co-morbid
CVD and depression reported the greatest deficits in AQOL
utility scores (Coef: -0.32, 95% CI: -0.40, -0.23), after
adjusting for covariates. Those with MDD only (Coef:
-0.27, 95% CI: -0.30, -0.24) and CVD only (Coef:
-0.08, 95% CI: -0.11, -0.05) also reported reduced
AQOL utility scores. Second, the influence of MDD and
CVD on HRQOL was shown to be additive, rather than
synergistic. Third, a significant dose–response relationship
was observed between depression severity and HRQOL.
However, CVD and depression severity appeared to act
independently of each other in impacting HRQOL.
Conclusions HRQOL is greatly impaired in individuals
with co-morbid MDD and CVD; these conditions appear to
influence HRQOL in an additive fashion. HRQOL alters
with depression severity, therefore treating depression and
improving HRQOL is of clinical importance.
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Introduction
Globally, cardiovascular disease (CVD) is the leading
cause of premature death [1] and major depressive disorder
(MDD) the top-ranking cause of disability [2]. While
individually, the health and economic burden of these
conditions is great, it is substantially more pronounced
when the two conditions co-occur. For example, patients
with CVD such as myocardial infarction (MI) who report
MDD are significantly more likely to experience poorer
health outcomes including increased morbidity, mortality
(including suicide) [3] and Coronary Heart Disease (CHD)
risk factor profiles, compared with those without depres-
sive symptoms.
Relationship between CVD, depression
and health-related quality of life (HRQOL)
While the relationship between MDD and CVD has been
extensively researched over the past 20 years, more
recently the role of HRQOL in this relationship has become
of interest. Although there are a range of definitions,
HRQOL most often comprises key aspects of functioning,
including mental, physical and social functioning. For
coronary patients, HRQOL outcomes have been shown to
be as important as any potential survival outcomes, in some
cases, of greater importance. Of survival gain, Rumsfeld
and Ho [4] argue that the benefits are ‘‘…limited to specific
patient subsets and many patients express a desire for
quality of life equal to or greater than their desire for
quantity of life’’. There is compelling evidence that
depression is the best predictor of HRQOL in MI popula-
tions, both in the short [5] and long term [6]. The impor-
tance of the role of depression in the HRQOL of CVD
patients has been highlighted when the influence of mental
health, as distinct from physical health [7], has been
examined. Findings from the Heart and Soul study identi-
fied depression, over physiological factors like left ven-
tricular ejection fraction and ischaemia, as having the most
important influence on HRQOL of cardiac patients. In fact,
this association is such that a dose–response relationship
exists between HRQOL and depression.
Dose–response relationship between HRQOL
and depression
Cross-sectional [7] and other studies [8] indicate that
depression severity increases synchronously with HRQOL
impairments. This dose–response relationship has been
demonstrated in cardiac, as well as other, populations.
However, the way in which the relationship between
depression and HRQOL is attenuated by the presence of
CVD remains less clear. Because HRQOL encompasses
both physical and mental health functioning, it would be
expected that the presence of co-morbid depression and
CVD, compared with the presence of major depression
alone, would exacerbate the effect between HRQOL and
depression observed in previous studies. However, to our
knowledge there is limited evidence to support this asser-
tion. An understanding of the way in which depression
severity interacts with CVD to influence overall HRQOL is
required to aid our knowledge of the complex relationship
between CVD, depression and HRQOL.
The impact of co-morbid depression and CVD
on HRQOL: synergistic or additive?
Indeed, the relative impact of chronic medical co-morbid-
ities on HRQOL has been investigated in order to deter-
mine whether the impact of disease on HRQOL is
synergistic or additive in nature. An additive effect sug-
gests that the combined effect of MDD and CVD on
HRQOL would approximate the sum of the independent
effect of each of these conditions, whereas a synergistic
relationship suggests that the combined effect is ‘‘greater
than the sum of the independent effect of each of these
conditions’’ [9].
To date, research exploring the additive and synergistic
effects of medical co-morbidities on HRQOL has revealed
disparate results, across disease populations. For individ-
uals with diabetes and other chronic medical co-morbidi-
ties, the impact of co-morbid conditions on HRQOL has
been shown to be additive, rather than synergistic [9]. In
contrast, research comprising Hepatitis C [10] populations
has revealed a synergistic influence of MDD and disease on
HRQOL. In those with CVD and diabetes specifically,
these conditions have been found to significantly interact
with one another to result in poorer functioning [11].
Previous research conducted in the 1980s suggested that
MDD and CVD may have an additive effect on well-being
and functioning; the combination of heart disease and
depression was shown to cause almost twice the social
38 Qual Life Res (2013) 22:37–44
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impairment caused by either condition alone [12]. How-
ever, the current understanding of the impact of MDD and
CVD on HRQOL using appropriate instruments, specifi-
cally designed to detect differences in HRQOL, is limited.
Identifying whether a synergistic relationship exists
between these two conditions in relation to HRQOL is
important for two key reasons. A condition such as MDD
may affect a patient’s behaviour in an adverse manner,
thereby impacting negatively on treatment outcomes for
CVD [13]. Alternatively, treating one condition may sub-
sequently impact on the other pre-existing condition,
resulting in lower HRQOL than would be expected as a
result of the pre-existing condition on its own.
The aim of the paper was to address the current research
gaps by using the Assessment of Quality of Life (AQOL)
instrument to (1) identify differences in HRQOL between
individuals with CVD, MDD, or both, compared to a
healthy reference group, (2) establish whether the influence
of co-morbid MDD and CVD on HRQOL is additive or
synergistic and (3) determine the way in which depression
severity interacts with CVD to influence overall HRQOL.
Methods
Study design and sampling
Cross-sectional, population-based data from the 2007
Australian National Survey of Mental Health and Well-
being (NSMHWB) were used. This methodology has been
described in detail elsewhere [14]. Briefly, the sample was
based on a stratified, multistage probability sample of
persons aged between 16 and 85 living in private dwellings
in Australia, excluding very remote areas. The overall
response rate was 60%, totalling 8841 participants. AQOL
utility scores were available for 8,820 participants.
Participants
Respondents with depression in the last 12 months were
identified using the Composite International Diagnostic
Interview (CIDI 3.0) [15], one of the most widely used,
structured diagnostic interviews for psychiatric disorders in
the world. Diagnostically, MDD is characterised by the
presence of severely depressed mood persisting for at least
2 weeks [16]. Respondents were identified as having CVD
on the basis of their response to the question ‘have you had
or been treated for a (new or recurrent) CVD condition
(e.g. heart attack, angina, high blood pressure) over the past
12 months?’ Research has shown a good correlation
between self-reported chronic diseases, such as diabetes,
heart disease and asthma and those identified in medical
records (e.g. j = 0.85 for diabetes mellitus [17]). This
process allowed us to classify people as those (1) without
MDD or CVD, (2) with MDD but not CVD, (3) with CVD
but not MDD and (4) with both MDD and CVD. The time
frame of 12 months was selected for each condition to best
reflect participants’ current disease status.
Data collection instruments
Depression and CVD
Between August and December 2007, specially trained
ABS interviewers carried out the assessments at partici-
pants’ private dwellings. All interviews were conducted
using a computer-assisted interview, which involved the
use of a notebook computer to record, store and transmit
the collected data. The CIDI 3.0 was administered to
diagnose depression. Information was collected to differ-
entiate between three types of depressive episodes, based
on the number of symptoms experienced by the participant:
Severe Depressive Episode (depressed mood; loss of
interest in activities; lack of energy or increased fatigue;
and additional symptoms (to total at least eight symp-
toms)); Moderate Depressive Episode (at least two of the
first three symptoms given above and additional symptoms
(to total at least six symptoms)); Mild Depressive Episode
(at least two of the first three symptoms from the above
list and additional symptoms (to total at least four
symptoms)[14].
Health-related quality of life
The Assessment of Quality of Life (AQOL-4D) instrument
[18] was used to assess HRQOL. It was originally devel-
oped to increase the sensitivity of multiattribute utility
measurement and has the ability to detect nuanced differ-
ences in HRQOL—including mental health [19]. The
AQOL-4D was the first HRQOL instrument to indepen-
dently model all the sub-dimensions of health (independent
living, social relationships, physical senses, psychological
well-being, and illness) and combine sub-models to obtain
a multiattribute utility score [19]. Scores from the first 4
dimensions form the multiattribute utility score. Each
individual dimension is weighted to produce a dimension
score between ‘dimension worst’ (0.0) and ‘dimension
best’ (1.0) health states. Dimension scores are then com-
bined to obtain an overall utility score ranging from worst
possible HRQOL state (-0.04) to death (0.00) to full
HRQOL (1.00). The AQOL-4D measure has maintained
structural independence between health dimensions while
simultaneously obtaining a high degree of descriptive
sensitivity [19]. Based on receiver operator characteristic
(ROC) curve analyses and relative efficiency estimates,
Osborne [20] concluded that this is a sensitive and
Qual Life Res (2013) 22:37–44 39
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responsive HRQOL measure. Because of its robust psy-
chometric properties and the brevity of the scale, the
AQOL-4D is considered a suitable instrument for epide-
miologic studies where HRQOL and utility data are
required. The AQOL-4D has also been used in mental
health [21] and cardiac populations [22].
Co-variates
Demographic information included age, sex, registered
marital status, area socioeconomic disadvantage (Decile
1–10; where 1 = most disadvantage and 10 = least disad-
vantage)) [14], country of birth, main language spoken at
home (English, other), rurality (residing in major urban,
other urban, other) [14], education (dichotomised into pre-
and post-graduate attainment) [14]. Data were also collected
to measure participants’ body mass index (BMI) (calculated
using the standard equation of weight divided by height
squared [23]), psychological distress (Kessler-10)) [24] and
current smoking status [14]. Social support was measured
according to frequency of social networking with friends and
family (nearly every day, 3–4 days a week, 1–2 days a week,
1–3 days a month, less than once a month; or never). Phys-
ical activity in the past week (number of times spent walking
for recreation, exercise or gain) was measured using a widely
used and validated instrument [14, 25].
Data analysis
Data were provided by the Australian Bureau of Statistics
from a Confidentialised Unit Record File. Estimates and
standard errors (SE) were derived using a complex esti-
mation procedure to account for the stratified multistage
survey design, oversampling and non-response [14], using
the Jackknife delete-2 technique. The use of Jackknife
techniques is commonly used for the analysis of complex
survey data. It involves deleting one sample primary
sampling unit (PSU) at a time to form replicates, and re-
weighting every replicate as necessary in order to make
inference to the population represented by the full sample.
Using these replicates, it is possible to calculate the stan-
dard error, using the delete-a-group Jackknife standard
error estimator [26]. Probability (sampling) weights were
applied to weight the sample back to the population from
which the sample was drawn.
Using methods described by Hosmer and Lemeshow [27],
linear regression was performed to assess differences in
AQOL utility scores across disease groups, the synergistic
effect of disease on HRQOL, and dose–response effects
between AQOL utility scores and recent depression severity
over the past 12 months. Algorithms for AQOL scoring
were obtained from http://www.aqol.com.au/scoring-algo
rithms.html. Where negatively skewed (AQOL utility
scores), data were transformed using the appropriate log
transformations (loge transformation^3). Post-estimation
tests were conducted for final regression models. Measures
of magnitude were presented as adjusted Coefficients with
Jackknife SEs and 95% confidence intervals (CIs). Syner-
gistic effects of CVD and MDD were assessed by the addi-
tion of a CVD/MDD interaction with a model containing
separate main effects terms: CVD over the past 12 months
(yes/no) and MDD over the past 12 months (yes/no). Stata 11
(survey procedures) was used for all statistical analyses.
STROBE guidelines (20) were applied for the reporting of
cross-sectional studies.
Results
The key characteristics for all survey participants are dis-
played in Table 1, by disease status (n = 8841). Those
belonging to the healthy reference group comprised the
greatest proportion of individuals with a post-graduate
education and non-English speaking individuals. Those
with co-morbid CVD and MDD had the highest proportion
of individuals belonging to a lower socio-economic
bracket, reporting lowest physical activity frequency, and
highest psychological distress and BMI. Those with MDD
only reported the youngest mean age. Of those belonging to
this sub-group, almost two-thirds were single. This sub-
group comprised the greatest proportion of smokers and the
most frequent physical activity over the previous week.
Those with CVD only were least likely to be single,
reported the highest mean age of CVD onset and mean age.
Approximately 10% of the overall sample (10.3%, 95% CI:
9.6, 11.1) reported having ever received helpful or effective
treatment for depressive symptoms (sadness/lack of inter-
est); 28.3% (95% CI: 20.4, 36.2) of the MDD and CVD
group and 30.7% (95% CI 27.6, 33.9) of the MDD only
group.
AQOL utility scores were available for 8,820 participants.
Of those respondents for whom AQOL utility scores were
not available (n = 21), none belonged to the co-morbid
CVD/MDD group; 13 belonged to the reference group, three
were from the MDD only group and five were from the CVD
only group. Overall, they were older, comprised more men,
belonged to a lower socio-economic bracket and reported
higher psychological distress, when compared with those for
whom full data were available. After controlling for sex,
age, marital status, education, area disadvantage, rurality,
smoking, social support, BMI, employment status, a multi-
variate linear regression model revealed significant impair-
ments in AQOL utility scores in all three disease groups,
compared with a healthy reference group (Table 2). Of
all the groups, individuals with co-morbid depression and
CVD reported the lowest AQOL utility scores (Coef: -0.32,
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95% CI: -0.40, -0.23). Those with MDD only (Coef:
-0.27, 95% CI: -0.30, -0.24) and CVD only (Coef: -0.08,
95% CI: -0.11, -0.05) also reported reduced AQOL utility
scores. In addition to exploring the impact of disease on
overall AQOL utility score, we re-ran these analyses for each
AQOL dimension (independent living, social relationships,
physical senses, mental health). We observed similar trends
in impairment by disease group for each dimension of
HRQOL (data not shown).
To explore whether the impact of this co-morbidity was
additive or synergistic, we undertook another multivariate
linear regression analysis. After adjusting for sex, age,
marital status, education, area disadvantage, rurality,
smoking, social support, BMI and employment status, the
model revealed a non-significant interaction between CVD
and MDD (adjusted coefficient: 0.03, 95% CI: -0.06, 0.12;
p = 0.52), suggesting the relationship may be additive,
rather than synergistic.
Next, we explored whether a dose–response relationship
exists between MDD severity and HRQOL. After adjusting
for sex, age, marital status, smoking, social support, BMI,
employment status and CVD-MDD severity interaction, a
regression model revealed a significant relationship
between MDD severity and HRQOL (Mild; Coef: -0.16,
95% CI: -0.20, -0.12, Moderate; Coef: -0.28, 95% CI:
-0.32, -0.24, Severe; Coef: -0.47, 95% CI: -0.51, -0.43)
(Table 3). This relationship is displayed in Fig. 1, where an
increase in depression severity is shown to be associated with
greater deficits in AQOL utility score. We then entered CVD
and MDD severity into the model as an interaction term. The
interaction failed to reach significance, suggesting that CVD
and depression severity may act independently to impact
HRQOL, rather than synergistically.
Discussion
Our finding that impairments in HRQOL are greatest for
those with co-morbid MDD and CVD is consistent with
studies of clinical populations, which have demonstrated
the magnified effects of this co-morbidity on HRQOL [5].
These results add to the literature by providing robust
evidence of these disease-related impairments at the pop-
ulation level. Our findings are potentially more represen-
tative than other studies, where estimates derived from
clinical populations may be skewed towards more severe
health states. While our second finding that the influence of
MDD and CVD on HRQOL is additive, rather than syn-
ergistic, is consistent with some studies of other medical
co-morbidities on HRQOL [9], to our knowledge, ours is
the first to attempt to disentangle the independent effects of
CVD and MDD on HRQOL, using a measure of HRQOL
which specifically detects nuanced differences in HRQOL
[19]. Third, our finding of a significant dose–response
Table 2 Linear regression model for the relationship between log-









MDD only -0.27 -0.27 \0.00 -0.30 -0.24




-0.40 -0.32 \0.00 -0.40 -0.23
a Adjusted for sex, age, marital status, education, area disadvantage,
rurality, smoking, social support, BMI, employment status
Table 3 Linear regression model assessing dose–response relation-








Mild -0.14 -0.16 \0.00 -0.20 -0.12
Moderate -0.29 -0.28 \0.00 -0.32 -0.24
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Mild Depression Moderate Depression Severe Depression
AQOL utility score
AQOL utility score
Fig. 1 Dose-reponse relationship between AQOL utility score and
depression severity
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relationship between depression severity and HRQOL,
while consistent with studies comprising Coronary Artery
Disease populations [7], adds to the existing literature
because, to our knowledge, this is also the first time this has
been demonstrated in those with CVD, at the population
level. We chose to compare our findings with those of
clinical populations as we would expect those studies
comprising MI patient samples to show a more pronounced
dose–response effect between depression and HRQOL
because of the recency of the cardiac event and the like-
lihood of depression occurring in the first six months, post-
MI [28]. Our study provides a broader view of the rela-
tionship between depression and HRQOL in a wide sample
of individuals affected by a range of CVD, not restricted
only to those hospitalised as a result of MI. Thus, our
results are potentially more generalisable to the wider CVD
population, in addition to those experiencing post-MI
depression.
Indeed, our findings highlight the influence of co-morbid
depression (particularly of increasing severity) and CVD
on HRQOL status. There are a range of explanations
regarding the mechanisms that link MDD and CVD to
HRQOL. The observed deficits in HRQOL for those with
co-morbid CVD and MDD may reflect physical illness of
greater severity, which subsequently intensifies depression
severity. Conversely, increasing depression severity may
exacerbate an individuals’ perception of their functional
impairments. Indeed, our findings suggest that depression
severity is a stronger contributor to HRQOL impairments
than CVD; the presence of CVD does not appear to
attenuate the dose–response effects previously observed
between depression and HRQOL [7]. Depression man-
agement has been shown to improve HRQOL in patients
with depression [29]. However, in co-morbid populations,
given that the effects of MDD and CVD appear to act
independently of each other, we recommend that cardiac
rehabilitation programmes, which address lifestyle factors
be incorporated into depression treatment programmes if
overall HRQOL status (particularly physical functioning) is
to be improved. We further recommend that randomised
controlled trials, which evaluate the benefits of combined
depression treatment and lifestyle modification programmes
in CVD patients exhibiting depression be undertaken, with
the inclusion of HRQOL endpoints. Furthermore, the cost-
effectiveness of such a programme should be evaluated
from the perspective of each of the responsible fund-
holders (e.g. hospital cost-centres, hospital/health network,
state/federal health budgets) to determine the possible
business case for wide scale implementation [30]. Where
routine depression treatment is seldom available after a
cardiac event, and participation in cardiac rehabilitation
programmes is often low, offering alternative approaches
to treatment after a cardiac event could potentially reduce
the HRQOL burden. Contemporary approaches to treat-
ment using tele-health or web-based interventions could
promote uptake and adherence to rehabilitation, where
various logistic and other barriers (including depres-
sive symptoms) have been shown to impede participation
[31].
A strength of this study was the administration of a
diagnostic interview to assess MDD and the use of the
AQOL instrument and the utility scores it generates. A
further advantage of this study was its robustness and
representativeness due to the use of a large, probability
sample from the general population. Third, the use of the
AQOL instrument to measure HRQOL is advantageous; it
has been shown to have sound instrument sensitivity where
other HRQOL instrument sensitivity is questionable [32].
However, several limitations were observed. The cross-
sectional design of the study precludes us from determining
causality, or the long-term impact of co-morbid depression
and CVD on HRQOL in this population. Additional
research could use longitudinal or panel studies to explore
HRQOL trajectory and associated costs over time. Sec-
ondly, in the absence of objective data, CVD status was
determined by self-report. Further, CVD was defined as
‘‘any heart or circulatory condition’’. These measures may
have led to recall bias, misclassification or incorrect iden-
tification of CVD and possible dilution of the CVD effect.
Conclusions
Our assessment of the impact of co-morbid MDD and CVD
on HRQOL at the population level, as distinct from clinical
populations, provides an important snapshot of the current
burden of, and interaction between, CVD and a high
prevalence mental health disorder like depression in the
general population. Due to their increasing prevalence in
ageing Western populations, minimising the burden of their
consequences at the population level through prevention
and appropriate management remains paramount.
Acknowledgments This work was supported by a Post-Graduate
Award from the National Heart Foundation of Australia (PP
08M4079)(AO), a Diabetes UK Moffat Travelling Fellowship
(EDW), a NHMRC Health Services Research Grant (465130) (CES)
and an Australian Research Council Future Fellowship (FT991524)
(KS). The Commonwealth Department of Health and Ageing funded
the survey. The authors gratefully acknowledge the Australian Bureau
of Statistics for conducting the survey and providing the data.
Conflict of interest The authors have no competing interests to
declare.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
Qual Life Res (2013) 22:37–44 43
123
References
1. World Health Organisation. (2004). In J Mackay & G Mensah
(Eds.), The Atlas of heart disease and stroke. Geneva: WHO with
the US Centres for Disease Control and Prevention (CDC).
2. World Health Organisation. (2008). The global burden of disease
2004 update. Geneva.
3. Larsen, K. K., Agerbo, E., Christensen, B., Sondergaard, J., &
Vestergaard, M. (2010). Myocardial infarction and risk of sui-
cide: A population-based case-control study. Circulation, 122,
2388–2393.
4. Rumsfeld, J. S., & Ho, P. M. (2005). Depression and cardio-
vascular disease: A call for recognition. Circulation, 111(3),
250–253.
5. Lane, D., et al. (2001). Mortality and quality of life 12 months
after myocardial infarction: Effects of depression and anxiety.
Psychosomatic Medicine, 63(2), 221–230.
6. Drory, Y., Kravetz, S., & Hirschberger, G. (2002). Long-term
mental health of men after a first acute myocardial infarction.
Archives of Physical Medicine and Rehabilitation, 83(3),
352–359.
7. Ruo, B., et al. (2003). Depressive symptoms and health-related
quality of life: The heart and soul study. Journals American
Medical Association, 290(2), 215–221.
8. Stafford, L., et al. (2007). Comorbid depression and health-rela-
ted quality of life in patients with coronary artery disease. Journal
of Psychosomatic Research, 62(4), 401–410.
9. Wee, H.-L., et al. (2005). The impact of diabetes mellitus and
other chronic medical conditions on health-related quality of life:
Is the whole greater than the sum of its parts? Health and Quality
of Life Outcomes, 3(1), 2.
10. Lim, J. K., et al. (2006). The impact of chronic hepatitis C and
comorbid psychiatric illnesses on health-related quality of life.
Journal of Clinical Gastroenterology, 40(6), 528–534.
11. Oldridge, N. B., et al. (2001). Prevalence and outcomes of
comorbid metabolic and cardiovascular conditions in middle- and
older-age adults. Journal of Clinical Epidemiology, 54(9),
928–934.
12. Wells, K. B., et al. (1989). The functioning and well-being of
depressed patients. Results from the medical outcomes study.
Journals American Medical Association, 262, 914–919.
13. Zellweger, M. J., et al. (2004). Coronary artery disease and
depression. European Heart Journal, 25(1), 3–9.
14. Australian Bureau of Statistics. (2007). National survey of mental
health and wellbeing of adults, users’ guide. Canberra: ABS.
15. The World Health Organisation (WHO). (2011). Composite inter-
national diagnostic interview (CIDI) [cited 2011 April]; Available
from: http://www.hcp.med.harvard.edu/wmhcidi/index.php.
16. American Psychiatric Association. Diagnostic and statistical
manual of mental disorders, 4th edn. Text Revision: DSM-IV-TR.
Washington, DC: American Psychiatric Publishing, Inc.
17. Kriegsman, D. M., van Eijk, J. T., Boeke, A. J., & Deeg, D. J.
(1996). Self-reports and general practitioner information on the
presence of chronic diseases in community dwelling elderly.
Journal of Clinical Epidemiology, 49, 1407–1417.
18. Hawthorne, G., Richardson, J., & Osborne, R. (1999). The
Assessment of Quality Of Life (AQoL) instrument: A psycho-
metric measure of health-related quality of life. Quality of Life
Research, 8(3), 209–224.
19. Hawthorne, G., Richardson, J., & Day, N. (2000). Using the
Assessment of Quality of Life (AQoL) version 1.0. Melbourne:
Monash University.
20. Osborne, R. H., et al. (2003). Quality of life assessment in the
community-dwelling elderly: Validation of the Assessment of
Quality of Life (AQoL) instrument and comparison with the SF-
36. Journal of Clinical Epidemiology, 56(2), 138–147.
21. Goldney, R., et al. (2004). Subsyndromal depression: Prevalence,
use of health services and quality of life in an Australian popu-
lation. Social Psychiatry and Psychiatric Epidemiology, 39(4),
293–298.
22. Cheok, F., et al. (2003). Identification, course, and treatment of
depression after admission for a cardiac condition: Rationale and
patient characteristics for the identifying depression as a
comorbid condition (IDACC) project. American Heart Journal,
146(6), 978–984.
23. World Health Organisation. (2008). Global database on body
mass index. Geneva: World Health Organisation.
24. Kessler, R., & Mroczek, D. (1994). Final versions of our non-
specific psychological distress scale. Michigan: Institute for
Social Research, University of Michigan.
25. Booth, M. L., et al. (1996). Retest reliability of recall measures of
leisure-time physical activity in Australian adults. International
Journal of Epidemiology, 25(1), 153–159.
26. Australian Bureau of Statistics Methodology Advisory Commit-
tee. (2000). Weighting and standard error estimation for ABS
household surveys. [cited 2011 April]; Available from: http://
abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/1352.0.55.029Jul%
201999?OpenDocument.
27. Hosmer, D. W., & Lemeshow, S. (2000). Applied logistic
regression. New York: Wiley.
28. Schleifer, S. J., et al. (1989). The nature and course of depression
following myocardial infarction. Archives of Internal Medicine,
149, 1785–1789.
29. Schoenbaum, M., et al. (2002). The effects of primary care
depression treatment on patients’ clinical status and employment.
Health Services Research, 37(5), 1145–1158.
30. O’Neil, A., et al. (2011). A randomised, feasibility trial of a tele-
health intervention for acute coronary syndrome patients with
depression (‘MoodCare’): Study protocol. BMC Cardiovascular
Disorders, 11(1), 8.
31. Brual, J., et al. (2010). Drive time to cardiac rehabilitation: At
what point does it affect utilization? International Journal of
Health Geographics, 9(1), 27.
32. Hawthorne, G., Richardson, J., & Day, N. A. (2001). A comparison
of the Assessment of Quality of Life (AQoL) with four other generic
utility instruments. Annals of Medicine, 33(5), 358–370.
33. Hawthorne, G., & Osborne, R. (2005). Population norms and
meaningful differences for the Assessment of Quality of Life
(AQoL) measure. Australian and New Zealand Journal of Public
Health, 29(2), 136–142.
44 Qual Life Res (2013) 22:37–44
123
